AUREALIS THERAPEUTICS Trademark

Trademark Overview


On Wednesday, August 2, 2023, a trademark application was filed for AUREALIS THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the AUREALIS THERAPEUTICS trademark a serial number of 98113572. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Wednesday, July 3, 2024. This trademark is owned by Aurealis Therapeutics AG. The AUREALIS THERAPEUTICS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical and veterinary preparations, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; sanitary preparations for medical purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; dietetic food and substances, namely, fermented milk products, drinks and gum, adapted for medical or veterinary use; dietary supplements for humans and animals; health care products, namely, medical plasters, medical dressings, medicated ointments, medicated sprays, vaccine preparations, and human therapeutic agents for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; disinfectants; preparations for destroying vermin; fungicides and herbicides; pharmaceuticals, biosimilars, medicine, drugs, namely, immunomodulators and anticancer agents, antibodies, antibody fragments, checkpoint inhibitors and checkpoint...
aurealis therapeutics

General Information


Serial Number98113572
Word MarkAUREALIS THERAPEUTICS
Filing DateWednesday, August 2, 2023
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateWednesday, July 3, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical and veterinary preparations, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; sanitary preparations for medical purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; dietetic food and substances, namely, fermented milk products, drinks and gum, adapted for medical or veterinary use; dietary supplements for humans and animals; health care products, namely, medical plasters, medical dressings, medicated ointments, medicated sprays, vaccine preparations, and human therapeutic agents for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; disinfectants; preparations for destroying vermin; fungicides and herbicides; pharmaceuticals, biosimilars, medicine, drugs, namely, immunomodulators and anticancer agents, antibodies, antibody fragments, checkpoint inhibitors and checkpoint modifiers, vaccines, for human beings and animals; prokaryotic organisms, namely, genetically modified bacteria, bacteria producing growth factors, antibodies, immunomodulators, anticancer agents, checkpoint inhibitors and checkpoint modifiers and vaccines for medical use; medicines for human purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; medicines for veterinary purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; bacteriological preparations for medical and veterinary use, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; biological preparations for medical purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; biological preparations for veterinary purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; chemical preparations for medical purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; chemical preparations for pharmaceutical purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; chemical preparations for veterinary purposes, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer; pharmaceutical and veterinary preparations and substances in particular for the treatment of cancer, inflammatory diseases, immune system related diseases, specifically autoimmune disorders, and other conditions which can be treated or ameliorated by antibodies or antibody fragments binding to, activating or blocking of a target antigen or ameliorated by immunomodulating factors, namely, for tissue regeneration, treatment of chronic inflammatory diseases as well as autoimmune disorders and cancer
NOT AVAILABLETHERAPEUTICS

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, August 7, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAurealis Therapeutics AG
Party Type10 - Original Applicant
Legal Entity Type25 - NOT AVAILABLE
AddressBasel 4057
CH

Trademark Events


Event DateEvent Description
Saturday, August 5, 2023NEW APPLICATION ENTERED
Monday, August 7, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, April 3, 2024ASSIGNED TO EXAMINER
Wednesday, July 3, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, July 3, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, July 3, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, April 4, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, April 4, 2024NON-FINAL ACTION WRITTEN
Thursday, April 4, 2024NON-FINAL ACTION E-MAILED